Names and pronunciation
(TIH-suh-jen-LEK-loo-sel) Kymriah
PDF page 1301
Loading InternPractice…
Drug reference
(TIH-suh-jen-LEK-loo-sel) Kymriah
PDF page 1301
Func. class.: Antineoplastic
PDF page 1301
USES: For the treatment of refractory B-cell precursor acute lymphoblastic leukemia
PDF page 1301
Black Box Warning: Cytokine release syndrome, infection, neurotoxicity
PDF page 1301
DOSAGE AND ROUTES • Adult ≤25 yr/adolescent/child/infant/ neonate: IV (>50 kg): Infuse a single dose of 0.1-2.5 × 108 CAR-positive viable T cells (non–weight-based); (≤50 kg): Infuse a single dose of 0.2-5 × 106 CAR- T positive viable T cells per kg of body weight. Give at 2-14 days after the com- pletion of lymphocyte depletion with fludarabine and cyclophosphamide
PDF page 1301
Available forms: IV infusion single dose 10-50 mL with chimeric antigen receptor- positive viable T cell (infusion bag)
PDF page 1301
• Adult ≤25 yr/adolescent/child/infant/ neonate: IV (>50 kg): Infuse a single dose of 0.1-2.5 × 108 CAR-positive viable T cells (non–weight-based); (≤50 kg): Infuse a single dose of 0.2-5 × 106 CAR- T positive viable T cells per kg of body weight. Give at 2-14 days after the com- pletion of lymphocyte depletion with fludarabine and cyclophosphamide
PDF page 1301